Mild, transient sedation, light-headedness, or nausea are the most common effects.Rapid or excessive infusions can disturb electrolytes or cause fluid overload, though this is rare with proper dosing and monitoring
General Safety Profile Based on the preclinical dataset and the limited human exposure data: No prominent signal of hepatic, renal, or hematological toxicity at tested doses No prominent cardiovascular safety flag Pregnancy and lactation as with most research compounds, safety not established Long-term effects not characterized What Clinicians Should Actually Tell Patients For patients asking about 5-amino-1MQ, a reasonable response framework: What the compound is: A research-stage small molecule inhibiting NNMT with promising preclinical fat loss data
Phase 2: Establishment (weeks 5 to 12) Maintain your introduction concentration through the establishment phase
These include: Kidney Disease : Individuals with compromised kidney function should be cautious, as glutathione is processed by the kidneys, and excess supplementation could lead to complications
Longevity-focused patients typically run a corrective loading phase (weekly NAD+ for 24 weeks) then move to monthly maintenance, often layered with glutathione IV for antioxidant defence and personalised vitamin therapy based on lab markers
